Search - tctmd.com

Displaying 1 - 11 of 11

Sort: Relevancy | Date

ASNC Fighting Back Against Proposed Reimbursement Cuts for Amyloid Imaging

News Daily News

ASNC Fighting Back Against Proposed Reimbursement Cuts for Amyloid Imaging

Yael L. Maxwell

September 11, 2025

Vutrisiran, With the FDA’s Sign-off, Joins the Fray for ATTR-CM

News Daily News

Vutrisiran, With the FDA’s Sign-off, Joins the Fray for ATTR-CM

March 21, 2025

Even on Tafamidis, ATTR-CM Patients Face High Mortality Over Time

News Daily News

Even on Tafamidis, ATTR-CM Patients Face High Mortality Over Time

Michael O'Riordan

February 13, 2025

Acoramidis Approved in Europe for ATTR Cardiomyopathy

News Daily News

Acoramidis Approved in Europe for ATTR Cardiomyopathy

Michael O'Riordan

February 12, 2025

Top Heart Failure News of 2024

News Daily News

Top Heart Failure News of 2024

December 31, 2024

Before a Cardiomyopathy Diagnosis, TTR Destabilization Portends Higher Mortality

News Daily News

Before a Cardiomyopathy Diagnosis, TTR Destabilization Portends Higher Mortality

Yael L. Maxwell

December 12, 2024

FDA Approves First ‘Near-Complete’ Stabilizer to Treat ATTR Cardiomyopathy

News Daily News

FDA Approves First ‘Near-Complete’ Stabilizer to Treat ATTR Cardiomyopathy

November 25, 2024

Vutrisiran, an siRNA for ATTR-CM, Meets Primary Endpoint in HELIOS-B

News Daily News

Vutrisiran, an siRNA for ATTR-CM, Meets Primary Endpoint in HELIOS-B

Michael O'Riordan

June 24, 2024

FDA Decides Not to Approve Patisiran in ATTR Cardiomyopathy

News Daily News

FDA Decides Not to Approve Patisiran in ATTR Cardiomyopathy

October 10, 2023

Carpal Tunnel Syndrome Again Tied to Heart Failure: German Data

News Daily News

Carpal Tunnel Syndrome Again Tied to Heart Failure: German Data

July 19, 2023

ATTRibute-CM Top-Line Results Favorable for Acoramidis in Transthyretin Amyloidosis

News Daily News

ATTRibute-CM Top-Line Results Favorable for Acoramidis

July 17, 2023

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.